AARD

Aardvark Therapeutics' stock price has been significantly impacted by several events in the past six months. In February 2026, the company announced a voluntary pause of its Phase 3 HERO trial for ARD-101 due to "reversible cardiac observations," causing a 56.2% stock drop. In May 2026, the U.S. FDA placed a full clinical hold on ARD-101's investigational new drug application, leading to another 32.1% stock decline and analyst downgrades. These events have resulted in multiple securities fraud class-action lawsuits alleging the company overstated ARD-101's safety. The company reported Q2 2026 financial results in August 2026, and its stock price has lost 34.1% over the past 12 months.